Viking Therapeutics Files 8-K on Financials
Ticker: VKTX · Form: 8-K · Filed: Oct 22, 2025 · CIK: 1607678
Sentiment: neutral
Topics: financial-reporting, operations, sec-filing
Related Tickers: VKTX
TL;DR
Viking Therapeutics dropped an 8-K on Oct 22, 2025, updating financials and operations. Check it out.
AI Summary
Viking Therapeutics, Inc. filed an 8-K on October 22, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing provides an update on the company's financial status and operational performance.
Why It Matters
This filing provides investors with crucial, up-to-date information on Viking Therapeutics' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not appear to contain any new or significant risk-inducing information.
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Registrant
- October 22, 2025 (date) — Date of earliest event reported
- 001-37355 (company) — Commission File Number
- 46-1073877 (company) — IRS Employer Identification No.
- 9920 Pacific Heights Blvd, Suite 350 (company) — Address of Principal Executive Offices
- San Diego, California (company) — City and State of Principal Executive Offices
- 92121 (company) — Zip Code of Principal Executive Offices
- 858 704-4660 (company) — Registrant's Telephone Number
FAQ
What specific items are being reported in this 8-K filing?
This 8-K filing reports on the 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is October 22, 2025.
What is the Commission File Number for Viking Therapeutics, Inc.?
The Commission File Number for Viking Therapeutics, Inc. is 001-37355.
Where are Viking Therapeutics, Inc.'s principal executive offices located?
Viking Therapeutics, Inc.'s principal executive offices are located at 9920 Pacific Heights Blvd, Suite 350, San Diego, California 92121.
What is the telephone number for Viking Therapeutics, Inc.?
The telephone number for Viking Therapeutics, Inc. is 858 704-4660.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-10-22 16:10:27
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar
Filing Documents
- vktx-20251022.htm (8-K) — 45KB
- vktx-ex99_1.htm (EX-99.1) — 282KB
- img201808844_0.jpg (GRAPHIC) — 13KB
- 0001193125-25-246775.txt ( ) — 465KB
- vktx-20251022.xsd (EX-101.SCH) — 23KB
- vktx-20251022_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 22, 2025, we issued a press release reporting our financial results for the third quarter ended September 30, 2025 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No Description 99.1 Press release issued October 22, 2025, reporting financial results for the third quarter ended September 30, 2025 and providing a corporate update. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viking Therapeutics, Inc. Date: October 22, 2025 By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer (Principal Executive Officer)